Objective: Neuropathological studies have demonstrated that cerebrovascular disease and Alzheimer disease (AD) pathology frequently co-occur in older adults. The extent to which cerebrovascular disease influences the progression of AD pathology remains unclear. Leveraging newly available positron emission tomography (PET) imaging, we examined whether a well-validated measure of systemic vascular risk and β-amyloid (Aβ) burden have an interactive association with regional tau burden. Methods: Vascular risk was quantified at baseline in 152 clinically normal older adults (mean age = 73.5 AE 6.1 years) with the office-based Framingham Heart Study cardiovascular disease risk algorithm (FHS-CVD). We acquired Aβ ( 11 CPittsburgh compound B) and tau ( 18 F-flortaucipir) PET imaging on the same participants. Aβ PET was performed at baseline; tau PET was acquired on average 2.98 AE 1.1 years later. Tau was measured in the entorhinal cortex (EC), an early site of tau deposition, and in the inferior temporal cortex (ITC), an early site of neocortical tau accumulation associated with AD. Linear regression models examined FHS-CVD and Aβ as interactive predictors of tau deposition, adjusting for age, sex, APOE ε4 status, and the time interval between baseline and the tau PET scan. Results: We observed a significant interaction between FHS-CVD and Aβ burden on subsequently measured ITC tau (p < 0.001), whereby combined higher FHS-CVD and elevated Aβ burden was associated with increased tau. The interaction was not significant for EC tau (p = 0.16). Interpretation: Elevated vascular risk may influence tau burden when coupled with high Aβ burden. These results suggest a potential link between vascular risk and tau pathology in preclinical AD.
presence of cerebrovascular disease pathology at autopsy appears to lower the threshold at which a given burden of AD pathology leads to cognitive impairment and dementia, 8, 9 highlighting the critical importance of vascular pathologies to the emergence of clinically evident symptoms. Consistent with this, we recently demonstrated that higher levels of vascular risk and elevated β-amyloid (Aβ) burden synergistically accelerate cognitive decline in clinically normal older individuals. 10 Although vascular contributions to the clinical syndrome of AD have been increasingly recognized, 11 it remains unclear whether vascular burden influences the accumulation of AD pathology in vivo.
Multiple studies suggest that vascular risk factors assessed during midlife are associated with increased in vivo Aβ burden measured later in life. [12] [13] [14] However, the evidence is mixed as to whether a relationship exists between vascular risk factors and Aβ burden measured concurrently in older adults, 10, 12, 15 with recent data from our group suggesting no relationship. 10 In terms of tau burden, several studies have demonstrated a possible association between vascular risk factors and both cerebrospinal fluid (CSF) and positron emission tomography (PET) markers of tau deposition. 14, 16, 17 Additionally, a recent autopsy study identified an association between late life systolic blood pressure and tau pathology burden. 18 Motivated by these prior studies, in the present study we examined associations between vascular risk factors, Aβ burden, and regional tau burden in clinically normal older adults participating in the Harvard Aging Brain Study (HABS). Specifically, we combined the recently developed tau PET tracer 18 F-flortaucipir, 11 C-Pittsburgh compound B PET, and a well-validated measure of systemic vascular risk to investigate whether increased vascular risk and elevated Aβ burden are synergistically associated with higher regional tau burden in vivo. We primarily focused on tau burden in 2 regions of interest (ROIs): the entorhinal cortex (EC), because it is among the first regions to develop tau pathology with increasing age, 19, 20 and the inferior temporal cortex (ITC), as it is an early neocortical site of tau deposition associated with AD. 19, 21, 22 Subjects and Methods
Participants
One hundred fifty-two clinically normal participants from HABS were included in this study (see Table 1 for demographic information). Participants provided written informed consent prior to study procedures. Study protocols were approved by the Partners HealthCare Institutional Review Board. At study entry, all participants had a global Clinical Dementia Rating 23 = 0, had a Mini-Mental State Examination 24 ≥ 27 with educational adjustment, and performed within education-adjusted norms on Logical Memory delayed recall. 25 All participants underwent a comprehensive medical and neurological evaluation and none of the participants had serious medical, psychiatric, or neurological conditions, recent history of alcoholism, or drug abuse. Exclusionary criteria included a Modified Hachinski Ischemic Score > 4, history of stroke with residual deficits, and extensive small vessel ischemic disease. In the present study, participants were required to have both Aβ and tau PET imaging data, as well as the necessary demographic and medical information to calculate an aggregate measure of vascular risk.
Cardiovascular Disease Risk
Vascular risk was quantified using the office-based Framingham Heart Study cardiovascular disease risk score (FHS-CVD) 26 at year 1 of HABS (baseline). The FHS-CVD represents a weighted sum of age, sex, antihypertensive treatment (yes or no), systolic blood pressure (mmHg), body mass index (calculated as weight APOE ε4 = apolipoprotein E ε4 allele; Aβ = β-amyloid; BMI = body mass index; DVR = distribution volume ratio; EC = entorhinal cortex; FHS-CVD = Framingham Heart Study cardiovascular disease risk score; FLR = frontal, lateral temporal and parietal, and retrosplenial regional uptake; ITC = inferior temporal cortex; PET = positron emission tomography; PVC = partial volume corrected; SBP = systolic blood pressure; SD = standard deviation; SUVR = standardized uptake value ratio.
in kilograms divided by height in square meters), history of diabetes (yes or no), and current cigarette smoking status (yes or no). The FHS-CVD provides a 10-year probability of future cardiovascular events (defined as coronary death, myocardial infarction, coronary insufficiency, angina, ischemic stroke, hemorrhagic stroke, transient ischemic attack, peripheral artery disease, and heart failure). In our sample, the FHS-CVD ranged from 4% to 74% (median = 29%), with higher scores indicating greater risk of future cardiovascular events.
Brain Imaging
Aβ burden was measured using 11 C-Pittsburgh compound B PET, and tau burden was measured using 18 F-flortaucipir (previously known as AV-1451 or T807). PET imaging was carried out at the Massachusetts General Hospital PET facility (ECAT EXACT HR+ scanner; Siemens, Erlangen, Germany). Aβ PET data used in the present study were obtained during year 1 of HABS (baseline). Tau PET was introduced into HABS midstudy, with the majority of participants undergoing tau PET at year 4 of the study (2.98 AE 1.1 years after study entry). Detailed Aβ and tau PET protocols have been previously described. 21 As in prior studies from our group, Aβ PET measurements were represented as a distribution volume ratio across a composite of frontal, lateral temporal and parietal, and retrosplenial regions (given the high degree of collinearity among neocortical regions). 21, 27 Tau PET measures were computed as standardized uptake value ratios within FreeSurfer-defined (v5.3) ROIs. As mentioned above, we focused our analyses on 2 predefined ROIs: the EC and the ITC. Because we had no a priori hypotheses regarding laterality, regions were averaged across left and right hemispheres to reduce the number of comparisons. Due to offtarget binding of flortaucipir in the portions of the choroid plexus adjacent to the hippocampus, we did not examine tau burden in this region. 21, 28 Cerebellar gray matter (as defined by FreeSurfer) served as the reference region for Aβ and tau PET data. PET data were corrected for partial volume effects using the geometric transfer matrix method. 29 Of note, analyses using non-partial volume corrected PET data yielded nearly identical results (not reported).
Statistical Analyses
Statistical analyses were performed using R (v3.2.4). All continuous variables were z-transformed prior to model entry. We used partial Pearson correlations to examine the relationships between FHS-CVD, Aβ burden, and tau burden in the EC and ITC, adjusting for age and sex. Of primary interest in the present study was whether baseline FHS-CVD and Aβ burden interact to predict subsequent tau in the EC and ITC. We used linear regression models to examine this question, controlling for age, sex, apolipoprotein E (APOE) ε4 status (carrier/noncarrier), and the time interval between baseline and the tau PET scan (to account for differences across participants related to when tau PET was acquired). We next conducted an exploratory whole-brain regional analysis to examine whether the interaction of baseline FHS-CVD and Aβ burden on subsequent tau deposition extended to regions beyond the 2 prespecified ROIs examined in the primary analyses (EC and ITC). As above, this analysis averaged across left and right hemispheres, and we adjusted for age, sex, APOE ε4 status, and the time interval between baseline and the tau PET scan. Family-wise error (FWE) correction was used to maintain an α of ≤0.05 in the setting of multiple ROI comparisons (corresponds to an uncorrected p value of ≤0.0036).
Results
Baseline demographic information is presented in Table 1 . After adjusting for age and sex, there was no relationship between FHS-CVD and Aβ burden (r partial = −0.04, p = 0.59). We observed a significant but weak relationship between FHS-CVD and tau burden in the ITC (r partial = 0.19, p = 0.02). The relationship between FHS-CVD and tau burden in the EC was not statistically significant (r partial = 0.12, p = 0.15). Consistent with previous findings, 17,30,31 we found a significant relationship between Aβ and tau burden in both the EC (r partial = 0.50, p < 0.001) and ITC (r partial = 0.46, p < 0.001). A linear regression analysis suggested that APOE ε4 status was not related to FHS-CVD (β = −0.05, standard error = 0.12, p = 0.70) after adjusting for age and sex. The primary goal of the study was to investigate whether baseline FHS-CVD and Aβ burden have an interactive association with subsequent tau burden in 2 predefined ROIs (EC and ITC). We found a significant interaction between FHS-CVD and Aβ burden in relation to tau burden in the ITC, whereby the combination of higher FHS-CVD and higher Aβ burden was associated with elevated tau deposition in this region. We did not find a significant interaction between FHS-CVD and Aβ burden in predicting tau burden in the EC (Fig 1,  Table 2 ).
To explore whether the interaction of FHS-CVD and Aβ burden was limited to the ITC, we next performed an exploratory analysis across a wider set of FreeSurfer-defined cortical ROIs, averaged across hemispheres. After adjusting for covariates and employing FWE correction for multiple comparisons, we observed that higher FHS-CVD and higher Aβ burden were interactively associated with elevated tau deposition in medial temporal (parahippocampus), lateral temporal (ITC and banks of the superior temporal sulcus), and posterior cingulate regions (Fig 2) .
Lastly, we investigated whether specific components of the FHS-CVD were driving the aforementioned interaction with Aβ burden in relation to subsequent tau deposition in the ITC. To address this question, we decomposed the FHS-CVD into its constituent measures and interacted each vascular component with Aβ to predict subsequent ITC tau. As summarized in Table 3 , we observed a significant interaction between all components of the FHS-CVD and Aβ burden in relation to ITC tau, with the exception of a history of diabetes. However, it should be noted that the number of study participants with a history of diabetes was relatively small (n = 13, 9% of the sample; see Table 1 ).
Discussion
In this study of clinically normal older adults, we observed that higher vascular risk in the setting of elevated Aβ burden was associated with increased tau deposition in temporal neocortical regions known to be early sites of AD-related tau deposition. 19, 21 Importantly, these findings remained after adjusting for age, sex, APOE ε4 status, and the time interval between baseline and the tau PET scan. Although additional studies are necessary to confirm our findings, the present results suggest that vascular risk factors may influence the progression of tau pathology in individuals with elevated Aβ burden. A growing body of research supports the hypothesis that Aβ is necessary, but not sufficient, to predict imminent cognitive decline along the AD trajectory. [32] [33] [34] The present findings raise the possibility that elevated vascular risk may represent a "second hit" that further potentiates the spread of Aβ-related neocortical tau pathology. Given the close linkage of tau pathology to cognitive decline, 35, 36 the synergistic interaction between vascular risk and Aβ burden may be one route by which clinical symptoms associated with AD are manifested.
9,10,37-39
We did not observe a significant interaction between FHS-CVD and Aβ burden in relation to tau in the EC. One possible explanation for this observation is that the EC ROI is relatively small and may be susceptible to partial volume effects due to its shape and close proximity to CSF. Accordingly, measurements of tau PET in the EC may be noisier than the ITC even when partial volume correction is employed (as in the present analyses). Consistent with this possibility, an exploratory analysis suggested an interaction between FHS-CVD and Aβ burden on tau deposition in larger, neighboring medial temporal regions, namely parahippocampal cortices (another site of early tau deposition). 19, 20, 40, 41 Although these exploratory findings should be interpreted cautiously and require replication in larger samples, the pattern of results suggests that the interaction of FHS-CVD and Aβ may influence tau deposition in medial temporal, lateral temporal, and posterior cingulate regions.
The underlying mechanism by which vascular risk and Aβ pathology interact to promote elevated neocortical tau deposition remains unclear. Several studies suggest that cerebrovascular disease contributes to AD pathogenesis via altering Aβ production and/or clearance, 42, 43 with several recent studies demonstrating an association between midlife vascular risk factors and later-life Aβ burden.
12-14 However, we did not find evidence of a relationship between vascular risk and concurrent measures of Aβ burden in our sample. It is possible that the effects of vascular risk on tau burden may be mediated by toxic Aβ species not readily detected with PET imaging (eg, oligomeric Aβ species). 44, 45 Another possible explanation is that vascular disease may render neurons more vulnerable to the toxic effects of Aβ, in turn promoting neocortical tau deposition in injured neurons and subsequent trans-synaptic spread of pathologic tau species.
Although we were most interested in the FHS-CVD as an aggregate measure of vascular risk, we did examine whether specific components of the FHS-CVD were driving the interaction with Aβ burden in relation to ITC tau. In these analyses, all components of the FHS-CVD interacted with Aβ burden to significantly predict increased ITC tau deposition, with the exception of a history of diabetes. It should be noted, however, that only a small number of study participants reported a history of diabetes (n = 13, 9%), and therefore this latter finding should be interpreted with caution. Overall, the consistently observed synergistic interactions between individual vascular risk factors and Aβ burden on tau deposition support the robustness of our finding using a multivariate vascular risk measure, and highlight the utility of aggregate measures of vascular risk when investigating relationships between vascular health and tau pathology in preclinical AD.
As with other studies of this type, consideration of the study sample composition is highly relevant to the interpretation and generalizability of the results. HABS participants are generally well educated and predominately Caucasian, sample characteristics that may impact the generalizability of these findings. HABS excludes participants with evidence of extensive small vessel disease, stroke, uncontrolled diabetes, and unstable hypertension, and therefore our study sample may not be representative of individuals with very high levels of systemic vascular risk.
In addition, individuals with both high vascular risk and high Aβ burden are likely under-represented in the study sample, as they are more likely to be cognitively impaired and therefore excluded from study participation. Although these exclusionary criteria do not allow us to study the full spectrum of vascular risk, our results suggest that even relatively modest levels of vascular risk can interact with Aβ burden to increase neocortical tau pathology in clinically normal older adults. Several additional limitations should be noted. Our findings are based on cross-sectional data; longitudinal studies with serial PET imaging will be critical to understand the temporal relationships between vascular risk, Aβ burden, and tau accumulation. In addition, future work in this and other cohorts should examine the extent to which tau accumulation mediates the impact of elevated vascular risk on cognitive decline in individuals with elevated Aβ. 46 Finally, we interpret the interaction of FHS-CVD with Aβ burden to represent that higher vascular risk in the context of elevated Aβ burden gives rise to higher tau burden; however, alternate interpretations of these findings remain quite possible. That is, this same interaction can also be interpreted as higher Aβ burden in the setting of elevated vascular risk leading to greater tau deposition. As such, the results here do not address whether elevated Aβ burden precedes elevated vascular risk or vice versa. This caveat is particularly important in the present study, as individuals with the highest levels of vascular risk may not be well represented in the study sample.
In conclusion, our results suggest that elevated vascular risk may influence neocortical tau deposition when coupled with high Aβ burden. Given that tau PET will likely become increasingly integral to AD clinical trials, these findings indicate the importance of accounting for vascular risk when assessing tau accumulation in clinical research settings. Perhaps most importantly, these findings support the rationale behind interventional studies designed to decrease systemic vascular risk (alone or in combination with Aβ-lowering approaches) as a means of attenuating the progression of Aβ-related neocortical tau pathology. [47] [48] [49] 
